- Home
- PRAX vs LNN Comparison
PRAX vs LNN Comparison
Compare PRAX & LNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- LNN
- Stock Information
- Founded
- PRAX 2015
- LNN 1954
- Country
- PRAX United States
- LNN United States
- Employees
- PRAX N/A
- LNN N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- LNN Industrial Machinery/Components
- Sector
- PRAX Health Care
- LNN Industrials
- Exchange
- PRAX Nasdaq
- LNN Nasdaq
- Market Cap
- PRAX 950.8M
- LNN 1.5B
- IPO Year
- PRAX 2020
- LNN 1988
- Fundamental
- Price
- PRAX $44.03
- LNN $139.73
- Analyst Decision
- PRAX Strong Buy
- LNN Hold
- Analyst Count
- PRAX 9
- LNN 1
- Target Price
- PRAX $94.44
- LNN $136.00
- AVG Volume (30 Days)
- PRAX 383.5K
- LNN 83.9K
- Earning Date
- PRAX 11-05-2025
- LNN 10-23-2025
- Dividend Yield
- PRAX N/A
- LNN 1.02%
- EPS Growth
- PRAX N/A
- LNN 5.71
- EPS
- PRAX N/A
- LNN 6.96
- Revenue
- PRAX $7,765,000.00
- LNN $677,807,000.00
- Revenue This Year
- PRAX N/A
- LNN $13.09
- Revenue Next Year
- PRAX $22.22
- LNN N/A
- P/E Ratio
- PRAX N/A
- LNN $20.21
- Revenue Growth
- PRAX 338.45
- LNN 9.46
- 52 Week Low
- PRAX $26.70
- LNN $112.14
- 52 Week High
- PRAX $91.83
- LNN $150.96
- Technical
- Relative Strength Index (RSI)
- PRAX 48.77
- LNN 51.76
- Support Level
- PRAX $37.25
- LNN $136.71
- Resistance Level
- PRAX $40.69
- LNN $141.06
- Average True Range (ATR)
- PRAX 2.54
- LNN 2.74
- MACD
- PRAX -0.03
- LNN 0.10
- Stochastic Oscillator
- PRAX 61.04
- LNN 60.39
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About LNN Lindsay Corporation
Lindsay Corp provides various proprietary water management and road infrastructure products and services. It has operations categorized into two main reporting segments: Irrigation, and Infrastructure. The company generates maximum revenue from the Irrigation segment. Its Irrigation segment includes manufacturing and marketing center pivot, lateral move, and hose reel irrigation systems, as well as various technology solutions such as GPS positioning and guidance, variable rate irrigation, wireless irrigation management, M2M communication technology, and smartphone applications. Geographically, it derives a majority of its revenue from the United States.